A prospective analysis of clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in an adult general practice population
- PMID: 39540993
- DOI: 10.1007/s10096-024-04989-3
A prospective analysis of clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in an adult general practice population
Abstract
Purpose: Dientamoeba fragilis is a protozoan frequently encountered in stool samples globally. It is debated whether Dientamoeba fragilis carries pathogenic capacities. This study prospectively analyses clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in a general practice adult population.
Methods: In this prospective observational cohort study 113 adult patients with a positive Polymerase Chain Reaction (PCR) test result for D. fragilis (T0) in a primary care setting, were followed-up longitudinally with a control PCR-test and microscopic stool examination at 30 days (T1) and 90 days (T2) after inclusion. Standardized patient-reported questionnaires including treatment details and the adjusted Irritable Bowel Syndrome-Severity Score (IBS-SS) were retrieved at T0, T1 and T2.
Results: Parasitology and questionnaires were retrieved from 87 participants at T0 and T1, and 74 at T2. Treated patients(n = 64) more often tested PCR negative at T1 (64.1% vs. 16.4%, p < 0.001) and T2 (67.3% vs. 5.3%, p < 0.001) compared to untreated patients. No difference in decline in IBS-SS was seen comparing the treatment and non-treatment groups at T1 (p = 0.403) or T2 (p = 1.00).
Conclusion: A short and long term increased parasitological clearance is shown with treatment of clioquinol or metronidazole compared with no treatment. A clear and significant correlation between parasitological cure and decline of clinical complaints as reported by the participants could not be established.
Keywords: Dientamoeba fragilis; Clinical outcome; Pathogenicity; Treatment.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
References
-
- Barratt JLN, Harkness J, Marriott D, Ellis JT, Stark D (2011) A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness. Gut Microbes 2(1):3–12. https://doi.org/10.4161/gmic.2.1.14755 - DOI - PubMed
-
- Stark D, Barratt J, Chan D, Ellis JT (2016) Dientamoeba fragilis, the neglected trichomonad of the human bowel. Clin Microbiol Rev 29(3):553–580. https://doi.org/10.1128/CMR.00076-15 - DOI - PubMed - PMC
-
- Garcia LS (2016) Dientamoeba fragilis, one of the neglected intestinal Protozoa. J Clin Microbiol 54(9):2243–2250. https://doi.org/10.1128/JCM.00400-16 - DOI - PubMed - PMC
-
- Munasinghe VS, Vella NGF, Ellis JT, Windsor PA, Stark D (2013) Cyst formation and faecal-oral transmission of Dientamoeba fragilis - the missing link in the life cycle of an emerging pathogen. Int J Parasitol 43(11):879–883. https://doi.org/10.1016/j.ijpara.2013.06.003 - DOI - PubMed
-
- Stark D, Beebe N, Marriott D, Ellis J, Harkness J (2005) Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 43(6):2718–2723. https://doi.org/10.1128/JCM.43.6.2718-2723.2005 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
